Therapeutic injections

Neonatal mouse pups, obtained within less than 16 h after birth, are injected in one eye with the therapeutic viral vector. The contralateral eye serves as a control and may remain uninjected, be mock-injected with carrier solution, or be injected with a non-therapeutic vector as the experiment indicates. Having determined that mock-injection or non-therapeutic injection did not impact the experimental model, our subsequent control eyes were uninjected. 

Small-volume injectables can be therapeutic injections, ophthalmics, diagnostics, radiopharmaceuticals, or allergenic extracts. The active ingredients can be intended for human or animal therapy and can be small molecules, proteins and other large molecules, biologies, vaccines, monoclonal antibodies, antisense oligonucleotides, and, in the future, genes. 

Hutt N, Kopferschmitt-Kubler M, Cabahon J, Purohit A, Alt M, Pauli G. Anaphylactic reactions after therapeutic injection of mistletoe Viscum album L.). Allergol Immunopathol (Madr) 2001 29(5) 201-3. 

A 22-G needle can be used for most therapeutic injections as it can reach most superficial musculoskeletal structures in children but a larger bore needle is usually required for aspiration. For therapeutic injections, usually a mixture of depomedrone and bupivacaine 0.5% is administered, with the dose varying according to the age of the child and the region being injected. 

The use of angled wire screens fixed or revolving have also been described for this purpose. The mice fall from these screens when they exhibit a condition of hypoglycaemia prior to convulsion or hypoglycaemic collapse. In this condition it is claimed that they can partake of food presented to them and thus avoid the need for a therapeutic injection of glucose. 

Intravenous aqueous injections provide an excellent means of achieving a rapid therapeutic response. Parenteral product design, eg, vehicle and other excipient selection, as well as choice of route of adrninistration, can prolong therapeutic activity and increase onset times. Thus, oily solutions, suspensions, or emulsions can be adrninistered by subcutaneous or intramuscular routes to create prolonged effect, ie, depot injection (28). 

Prolonged Action Parenterals Injections. Intramuscular injections have been developed to achieve prolonged therapeutic effects. This can be accompHshed by suspension of dmg particles in oils or flowable gels, from which the dmg slowly diffuses. Aqueous suspensions can also provide such therapeutic response. In these cases, the soHd dmg crystals generally are quite water insoluble and of a controlled particle size and crystallized form. 

In order to induce a toxic effect, local or systemic, the causative material must first come into contact with an exposed body surface these are the routes of exposure. In normal circumstances, and depending on the nature of the material, the practical routes of exposure are by swallowing, inhalation, and skin and eye contact. In addition, and for therapeutic purposes, it may be necessary to consider intramuscular, intravenous, and subcutaneous injections as routes of adininistration. 

An hplc assay was developed suitable for the analysis of enantiomers of ketoprofen (KT), a 2-arylpropionic acid nonsteroidal antiinflammatory dmg (NSAID), in plasma and urine (59). Following the addition of racemic fenprofen as internal standard (IS), plasma containing the KT enantiomers and IS was extracted by Hquid-Hquid extraction at an acidic pH. After evaporation of the organic layer, the dmg and IS were reconstituted in the mobile phase and injected onto the hplc column. The enantiomers were separated at ambient temperature on a commercially available 250 x 4.6 mm amylose carbamate-packed chiral column (chiral AD) with hexane—isopropyl alcohol—trifluoroacetic acid (80 19.9 0.1) as the mobile phase pumped at 1.0 mL/min. The enantiomers of KT were quantified by uv detection with the wavelength set at 254 nm. The assay allows direct quantitation of KT enantiomers in clinical studies in human plasma and urine after adrninistration of therapeutic doses. 

Cephalosporins first entered the marketplace in 1964, when cephalothin (27) and cephaloridine (51), which are both injectable, were launched. By the late 1970s, the injectable cephalosporins had become important therapeutic agents in the hospitals. Also in 1964 the first oral cephalosporin, cephaloglycin [3577-01 -3] C gH N OgS, was launched only to be displaced by the end of the year by cephalexin (12). For years cephalexin was the leading oral cephalosporin on the market. It has since been displaced by cefaclor (13). With the advent of the more -lactamase stable cephalosporins such as cefoxitin (23) and cefuroxime (35), and the more potent agents such as cefotaxime (36) and other third-generation compounds, cephalosporins now dominate the antibiotic market worldwide. 

Because bretylium is poody absorbed from the GI tract (- 10%), it is adrninistered iv or im. Very litde dmg is protein bound in plasma. Bretylium is taken up by an active transport mechanism into and concentrated in postganglionic nerve terminals of adrenergicahy innervated organs. Peak plasma concentrations after im injections occur in about 30 min. Therapeutic plasma concentrations are 0.5—1.0 p.g/mL. Bretylium is not metabolized and >90% of the dose is excreted by the kidneys as unchanged dmg. The plasma half-life is 4—17 h (1,2). 

The fact that ceU culture-derived products are often injected into humans as therapeutic agents makes it imperative that there be no component in the final product that can pose a potential health risk to the patient. Health risks can be introduced into a product from many sources including the ceUs themselves raw materials, such as semm, media components, etc materials used in purification, eg, antibodies and external contamination. Eor a therapeutic product such risk factors are identified at the outset and ways of reducing them to acceptable levels are designed into the process. Before a product is released by the EDA the manufacturer has to demonstrate this risk reduction by rigorous validation of the process. 

Antihemophilic factor [9001-28-9] (AHF) is a protein found in normal plasma that is necessary for clot formation. It is needed for transformation of prothrombin to thrombin. Administration of AHF by injection or infusion can temporarily correct the coagulation defect present in patients with hemophilia. Antihemophilic factor VIII (Alpha Therapeutic) has been approved by the FDA as replacement therapy in patients with hemophilia B to prevent bleeding episodes, and also during surgery to correct defective hemostasis (178). 

Therapeutic Function Hypoglycemic Chemical Name Isophane insulin Common Name Isophane insulin injection... 

The therapeutic utility of systemically administered ASON had been limited by their short plasma half life (sometimes even less than 3 min). This is due to their sensitivity to nuclease digestion. When the first-generation ASON were chemically modified, e.g., by replacing the oxygen in the phosphodiester bond with sulfur (phosphorothiorate) they obtained an increased stability in biological fluids while their antisense effect has been maintained. First-generation agents can be delivered via intravitreal injection, parenterally, by topical cream, enema, and inhaled aerosol. These antisense... 

Commercially available dtugs used for therapeutic therapy comprise up to date mainly injectable monoclonal antibodies like Infliximab (Remicade ) and Adalimumab (Humira ) or TNF-receptor derivatives like Etanercept (Enbrel ) (Fig. 3). One possible way of action of these reagents is the neutralization of TNF, thereby blocking its inflammatory effects and dampening (auto)immune responses [3, 4]. 

---